Breast Cancer :: Update on familial breast cancer guideline
The National Institute for Health and Clinical Excellence (NICE) and the National Collaborating Centre for Primary Care have published an update of its familial breast cancer guideline.
Care
Candidiasis :: Schering-Plough’s NOXAFIL, Posaconazole for Treatment of Oropharyngeal Candidiasis OPC
Schering-Plough Corporation (NYSE: SGP) reported that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL(R) (posaconazole) Oral Suspension for the treatment of oropharyngeal candidiasis (OPC), including infections refractory to itraconazole and/or fluconazole. OPC is a fungal infection of the mouth and throat caused by the yeast Candida. NOXAFIL is a novel triazole antifungal agent discovered and developed by Schering-Plough Research Institute.
Contraception :: IUC is a preferred contraceptive of female
Intrauterine contraception (IUC) is very effective, with a failure rate of less than one percent (similar to that of sterilization), which is one reason why many female ob/gyns choose this method of birth control for themselves. In fact, research shows that female ob/gyns are nine times more likely to choose an IUC for themselves compared with women in general. Misinformation and misperceptions about the IUC may have contributed to its limited use among women in the U.S. to date.
Constipation :: Unfounded fear of addiction prevents laxative use
Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show that many people wrongly fear that laxatives are addictive and that their use for long periods of time actually causes constipation.1,2
Herpes :: Merck’s shingles vaccine Zostavax, Zoster Vaccine Live for herpes zoster
Merck & Co., Inc. announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend that adults 60 years of age and older be vaccinated with ZOSTAVAX? [Zoster Vaccine Live (Oka/Merck)] to help prevent shingles (herpes zoster), a frequently painful disease marked by a blistering rash.
Health :: Bayer HealthCare acquires western OTC cough & cold business of Topsun Science and Technology
Bayer HealthCare (BHC) and Topsun Science and Technology Co., Ltd. (Topsun, 600771.SS) together announced that BHC’s Consumer Care Division has signed an agreement in China to acquire the Western over-the-counter (OTC) cough and cold portfolio of Topsun Science and Technology Qidong Gaitianli Pharmaceutical Co., Ltd. for the consideration of RMB 1,072 million (approximately EUR 103 million) plus contingent payments of RMB 192 million (approximately EUR 19 million) subject to fulfilment of certain performance criteria.
Tooth Decay :: New Weapon in Fight Against Tooth Decay
A group of scientists representing the UCLA School of Dentistry; the UCLA Department of Microbiology, Immunology and Molecular Genetics, and C3 Jian Corporation have succeeded in creating a pheromone-guided “smart” anti-microbial peptide capable of selectively eliminating Streptococcus mutans, a leading bacterial cause of tooth decay, in 30 seconds.
HIV :: Most HIV infected individuals with inadequate outpatient medical care
In a first-of-its-kind study, UCLA researchers have shown that segments of the HIV-infected population who have little to no consistent outpatient medical care ? and yet are most in need of such services ? are overwhelmingly minorities, the poor and substance abusers.
Imaging :: MRI Scans by Remote Control
UCLA radiologists and Siemens Medical Solutions have jointly developed remote-control software that enables an off-site imaging expert to log onto a personal computer and operate a magnetic resonance imaging (MRI) machine by remote control. Reported in the November issue of Radiology, the study found that the quality of the remote scans were superior to onsite scans by a less experienced technologist, suggesting options for helping facilities or regions with limited medical staff and expertise.
Crohn’s Disease :: Promising results in tough-to-treat crohn’s disease patients
Abbott announced results from a study showing HUMIRA? (adalimumab) induced significantly higher rates of clinical remission compared to placebo in patients with moderately to severely active Crohn’s disease who lost response to, or were intolerant to, infliximab therapy. The data is being presented simultaneously at the American College of Gastroenterology (ACG) annual meeting in Las Vegas and the United European Gastroenterology Week (UEGW) in Berlin.